Please assess the completion status of the following clinical trial:

Trial Title: Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Signature of informed consent~* COPD patients with age raging from 50 to 85 years old~* Patients with at least a history of COPD of one year~* COPD patients clinically stable in the last three months~* COPD subjects with FEV1 (Forced Expiratory Volume in 1st second)\<70% of predicted value~* FEV1/FVC (Forced Expiratory Volume in 1st second/Forced Vital Capacity) \<88% (males) or \<89% (females) of LLN (Low Levels of Normality)~* COPD former or active smokers with at least a smoking history of 20 pack year~Exclusion Criteria:~* Acute Bronchial Exacerbation at recruitment~* Fertile women with age between 18 and 50 years old or with active period~* Pregnancy~* Subjects enrolled in other clinical trials or that have taken part in one of them in the month preceding the enrollment.~* FEV1/FVC more than 70% of predicted value in basal conditions~* FEV1 more than 70% of predicted value in basal conditions~* Known deficit of alpha 1 antitrypsin~* Subjects that underwent a Lung Volume Reduction Surgery (LVRS)~* Subjects with known positivity to Human Immunodeficiency Virus (HIV)~* Misuse of alcool or drugs~* Lack of compliance in performing respiratory tests~* Subjects not capable to follow the study prescriptions because of psychic disorders or language problems.~* Long Term Oxygen Therapy with flows \> 6 litres per minute (l/min) at rest

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Formoterol Fumarate (Type: EXPERIMENTAL): At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
- Salmeterol (Type: ACTIVE_COMPARATOR): The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).